Insider Trading History of Maimon Yossi

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) by Maimon Yossi since 2008. The trader's CIK number is 1385115. At the time of the last reporting, Maimon Yossi was the VP, Chief Financial of Protalix Biotherapeutics, Inc.. (stock ticker symbol PLX). Also see all insider trading activities at Protalix Biotherapeutics, Inc..


Yearly summary of insider trading at Protalix Biotherapeutics, Inc. (PLX) by Maimon Yossi

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2015 PLX 10,000 $7,800 0 $0 0 $0
2012 PLX 0 $0 125,964 $898,123 125,964 $228,120
2010 PLX 0 $0 140,000 $1,241,940 147,769 $143,631
2009 PLX 0 $0 278,590 $1,902,907 310,063 $301,379
2008 PLX 0 $0 33,300 $105,760 86,176 $83,763


Insider trading of Protalix Biotherapeutics, Inc. (PLX) by Maimon Yossi

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2015-12-14 PLX Buy 10,000 .78 7,800
2012-05-02 PLX Option Ex 125,964 1.81 228,120
2012-05-02 PLX Sale 125,964 7.13 898,123
2010-10-07 PLX Option Ex 77,769 .97 75,591
2010-10-07 PLX Sale 70,000 9.67 676,900
2010-09-07 PLX Sale 31,500 8.16 257,040
2010-09-07 PLX Option Ex 70,000 .97 68,040
2010-09-03 PLX Sale 38,500 8.00 308,000
2009-10-16 PLX Sale 40,300 9.35 376,805
2009-10-16 PLX Option Ex 167,698 .97 163,002
2009-10-15 PLX Sale 109,700 9.50 1,042,150
2009-07-07 PLX Option Ex 62,217 .97 60,474
2009-07-06 PLX Sale 40,000 5.13 205,200
2009-07-07 PLX Sale 10,000 5.01 50,100
2009-05-18 PLX Sale 30,000 4.00 120,000
2009-05-18 PLX Option Ex 40,348 .97 39,218
2009-03-13 PLX Option Ex 39,800 .97 38,685
2009-03-11 PLX Sale 8,849 2.30 20,352
2009-03-13 PLX Sale 7,500 2.23 16,725
2009-03-12 PLX Sale 32,241 2.22 71,575
2008-02-25 PLX Sale 33,300 3.18 105,760
2008-02-22 PLX Option Ex 86,176 .97 83,763

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Maimon Yossi (VP, Chief Financial of Protalix Biotherapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.